OTCM
UNVC
Market cap7mUSD
Jul 09, Last price
0.00USD
1D
-3.13%
1Q
40.45%
Name
Univec Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Univec, Inc. is a medical device firm that, through its various operating divisions, develops, licenses, and sells products across the United States and internationally. Its primary offerings include a range of auto-disable and safety syringes. These encompass 1cc AD-syringes, which can be used for both aspirating and non-aspirating procedures, typically for dispensing precise doses of allergy, immunization, and insulin medications. Univec also produces sliding sheath syringes, engineered to protect both patients and healthcare professionals from accidental needlestick injuries. Additionally, the company manufactures bifurcated needle safety syringes, specifically designed for administering smallpox vaccines, particularly in response to potential bioterrorist threats. Univec distributes its auto-disable and sliding sheath safety syringes to private hospitals, other healthcare facilities, and distributors within the U.S., as well as to governmental entities in developing countries. Furthermore, it offers an online system that assists pharmaceutical companies with the marketing, fulfillment, and tracking of drug samples, serving as a connector between pharmacies and managed payment providers. The company was founded in 1992 and is based in Baltimore, Maryland.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||